Gestational Diabetes Market

Global Gestational Diabetes Market Size is poised to reach USD 3.45 Billion by 2035

According to a research report published by Spherical Insights & Consulting, The Global Gestational Diabetes Market Is Expected To Grow From USD 1.94 Billion In 2024 To USD 3.45 Billion By 2035, At A CAGR Of 5.37% During The Forecast Period 2025-2035.

Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the Global Gestational Diabetes Market Size, Share, and COVID-19 Impact Analysis, By Diagnosis Type (Oral Glucose Tolerance Test, Fasting Blood Sugar Test, Random Blood Sugar Test, and Haemoglobin A1c Test), By Treatment Type (Dietary Changes, Insulin Therapy, Oral Medications, and Physical Activity), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035.  https://www.sphericalinsights.com/reports/gestational-diabetes-market

The gestational diabetes market refers to the worldwide industry driven by the increasing obesity rate, maternal age, and better diagnostic screening. The market encompasses the diagnosis (glucose tests), management (diet, insulin, drugs), and monitoring devices, with dietary management being the largest segment. Gestational diabetes is a type of high blood sugar (glucose) that is first diagnosed during pregnancy. Glycemic monitoring and insulin delivery are dramatically changing with CGM and insulin pump technologies, along with the use of nutrition-focused mobile applications for diabetes mellitus education. Innovation and market expansion are anticipated as a result of major players' growing R&D expenditures, partnerships & collaborations, and awareness campaigns. An increase in healthcare expenditure, policy changes & healthcare reforms, along with the growing prevalence of gestational diabetes, are several factors responsible for driving the market. The market is further driven by increasing advancements in medical technology, like continuous glucose monitors and mobile health apps. However, the high expense of insulin therapies and monitoring devices, limited awareness and concerns associated with overdiagnosis and overtreatment of gestational diabetes are challenging the market growth.

The oral glucose tolerance test segment dominated the market with the largest share of over 45.0% in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the diagnosis type, the gestational diabetes market is divided into oral glucose tolerance test, fasting blood sugar test, random blood sugar test, and haemoglobin A1c test. Among these, the oral glucose tolerance test segment dominated the market with the largest share of over 45.0% in 2024 and is projected to grow at a substantial CAGR during the forecast period. an oral glucose tolerance test is a standard component of prenatal care that examines body’s sugar metabolism. Because of its dependability, OGTT is widely used for diagnosis, which is driving the segmental market growth.  

The dietary changes segment accounted for the largest market share of about 28.5% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.

Based on the treatment type, the gestational diabetes market is divided into dietary changes, insulin therapy, oral medications, and physical activity. Among these, the dietary changes segment accounted for the largest market share of about 28.5% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Key strategies includes prioritizing high-fiber, low-GI foods, pairing carbs with protein/healthy fats, and avoiding sugary, processed foods. 

North America is expected to hold the majority share of the global gestational diabetes market during the forecast period.

North America is expected to hold the majority share of about 37.0% in the global gestational diabetes market during the forecast period. The U.S. is leading the North America gestational diabetes market, driven by high screening, adoption of advanced technology, and reliance on insulin. North America has a robust market ecosystem that includes the region's growing prevalence of obesity, advanced maternal age, and sedentary lifestyles. Due to their innovative gestational diabetes products and partnerships with other industry players.      

Asia Pacific is anticipated to grow at the fastest pace of about 10.0% CAGR in the global gestational diabetes market during the forecast period. China is a dominant country in the Asia Pacific region for the gestational diabetes market, owing to a large population base, increased rates of obesity, and an increased number of the maternal population. In the Asia Pacific gestational diabetes market, growing obesity rates, sedentary lifestyles, and growing urbanization in nations like China and India. Further, the launching of government guidelines for gestational diabetes has become a major driving factor in the market.  

Major vendors in the global gestational diabetes market are Abbott Laboratories, Roche Diagnostics, Becton Dickinson and Company, Medtronic, Dexcom, Ascensia Diabetes Care, Sanofi, Novo Nordisk, Johnson & Johnson, and Others.   

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Key Market Development 

• In March 2025, US pharma major Eli Lilly launched the much-awaited diabetes and obesity management drug Mounjaro in India at one-fifth of the US price.

• In March 2023, Abbott announced that the U.S. Food and Drug Administration (FDA) had cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system sensors for integration with automated insulin delivery (AID) systems

.

• In March 2023, Eli Lilly and Company announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month. 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the gestational diabetes market based on the below-mentioned segments

Global Gestational Diabetes Market, By Diagnosis Type

• Oral Glucose Tolerance Test
• Fasting Blood Sugar Test
• Random Blood Sugar Test
• Haemoglobin A1c Test

Global Gestational Diabetes Market, By Treatment Type

• Dietary Changes
• Insulin Therapy
• Oral Medications
• Physical Activity

 Global Gestational Diabetes Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa